ClinicalTrials.gg
Not yet recruitingNCT05852288Updated May 10, 2023

Role of Inflammation in Carpal Tunnel Syndrome

An observational study in Carpal Tunnel Syndrome and Median Neuropathy, Carpal Tunnel, sponsored by Ahram Canadian University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-05-10.

Sponsored by Ahram Canadian University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2023, 3 years 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University — 5 open to participants now, 5 under way, none of them phase 3. Carpal Tunnel Syndrome · Ahram Canadian University.

Started
2023
with 9 others
Observational
7 of 10
5 open now
Registered
1st of 10
by date

Among the 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University, this one is one of 10 that started in 2023, is one of 7 observational ones, and was the 1st registered.

Carpal Tunnel Syndrome

591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.

Browse Carpal Tunnel Syndrome studies →

Open to participants now

5 of the 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University, or all of them as a file.
02

Study summary

This study aims to investigate the role of inflammation in carpal tunnel syndrome (CTS) using a prospective cohort study design. The study will involve a sample of at least 50 individuals with CTS who will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in CTS. The primary outcome measures include inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as clinical measures of CTS severity. Data will be analyzed using regression analysis to determine the relationship between inflammation and CTS. The study is expected to provide information on the role of inflammation in CTS and inform the choice of drug and concentration for transdermal drug administration.

03

Conditions studied

  • Carpal Tunnel Syndrome
  • Median Neuropathy, Carpal Tunnel
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will be recruited from a single center and will include at least 50 individuals with CTS. The population may include individuals of all ages, but the study will likely focus on middle-aged and older adults, as CTS is more common in this population.

The study population will be diverse in terms of gender and race/ethnicity to ensure that the study findings are generalizable to a broader population.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals aged 18 years or older
  • Diagnosis of carpal tunnel syndrome based on clinical symptoms and nerve conduction studies
  • Willingness and ability to provide to participate in the study
  • Willingness and ability to comply with study procedures and follow-up visits

Exclusion criteria

Exclusion Criteria:

  • Presence of other neurological conditions that may affect nerve function in the upper extremities
  • Use of medications that may affect inflammation or carpal tunnel syndrome severity
  • History of previous carpal tunnel release surgery on the affected wrist
  • Inability to comply with study procedures or follow-up visits
  • Pregnancy or breastfeeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Individuals with carpal tunnel syndrome

    This study will follow a group of individuals with carpal tunnel syndrome (CTS) according to Bland's grading scale (grades 1-3) to assess the role of inflammation in CTS. Participants will undergo clinical and biochemical evaluations to assess inflammatory markers and CTS severity. The study will follow participants over time to determine the relationship between inflammation and CTS, which can inform the choice of transdermal drug administration.

    Diagnostic Test: Inflammatory markers

Interventions

  • Diagnostic testInflammatory markers

    Participants in this cohort will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in CTS. The evaluation will include assessments of inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as clinical measures of CTS severity.

06

What researchers measure

Primary outcomes

  1. The relationship between inflammatory markers and symptom severity of carpal tunnel syndrome (CTS).

    interleukin-6, tumor necrosis factor-alpha using blood tests. Symptom severity will be assessed with standardized questionnaire "the Boston Carpal Tunnel Questionnaire".

    Time frame: Changes of inflammatory markers and symptoms severity at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline

  2. The relationship between inflammatory markers and grip strength of patients with CTS.

    interleukin-6, tumor necrosis factor-alpha using blood tests. functional status by grip strength using a dynamometer.

    Time frame: Changes of inflammatory markers and grip strength at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline

  3. The relationship between inflammatory markers and pinch strength of CTS patients.

    interleukin-6, tumor necrosis factor-alpha using blood tests. pinch strength will be measured using a dynamometer

    Time frame: Changes of inflammatory markers and pinch strength at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline

  4. The relationship between inflammatory markers and nerve conduction study of patients with CTS

    interleukin-6, tumor necrosis factor-alpha using blood tests. Nerve conduction study results (motor and sensory distal latency of median nerve and amplitude) will be used to determine CTS severity based on Bland's grading scale.

    Time frame: Changes of inflammatory markers and nerve conduction study at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The individual participant data (IPD) collected during this study will be available upon reasonable request. Requests for access to the data should be submitted via email to mohamed.elmeligie@acu.edu.eg. All requests will be reviewed by the study investigators to ensure that they are reasonable and consistent with the ethical principles of the study. Access to the data will be granted in compliance with applicable laws and regulations, and with appropriate safeguards to protect the privacy and confidentiality of study participants.

Supporting information: Statistical analysis plan, Informed consent form

Time frame: After finishing the trial and up to 1 year.

Access criteria: via email to mohamed.elmeligie@acu.edu.eg

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2023; primary completion for Sep 2023, 3 months later.

Of 40 non-industry observational studies under Carpal Tunnel Syndrome, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's planned 3 months is below that.

Counting every sponsor, half of 42 studies reached it within 18 months; a quarter within 11 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2023
First posted
May 10, 2023
StartEst.
May 15, 2023
Primary completionEst.
Sep 1, 2023
CompletionEst.
Sep 15, 2023
Last update
May 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05852288
Lead sponsor
Ahram Canadian University
Responsible party
Mohamed Magdy ElMeligie (Lecturer of Physical Therapy and Director of Electromyography Lab, Ahram Canadian University) — Principal investigator
First posted
May 10, 2023
Start date
May 15, 2023 (estimated)
Primary completion
Sep 1, 2023 (estimated)
Completion
Sep 15, 2023 (estimated)
Last update
May 10, 2023

Study contacts

Mohamed M ElMeligie, Ph.d
Contact
mohamed.elmeligie@acu.edu.eg
+201064442032
Amal Fawzy, Ph.d
study chair · Faculty of Physical Therapy, Ahram Canadian University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion